Atreya Dash, Matthew D. Galsky, Andrew J. Vickers, Angel M. Serio, Theresa M. Koppie, Guido Dalbagni and Bernard H. Bochner Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder Cancer 107
Version of Record online: 13 JUN 2006 | DOI: 10.1002/cncr.22031
Cisplatin-based combination perioperative chemotherapy has been shown to improve survival in patients with high-risk localized urothelial carcinoma of the bladder. However, the widespread use of such treatment may be limited by the high frequency of baseline renal impairment in this patient population. Using a cutoff creatinine clearance of <60 mL/min (calculated by Cockroft-Gault) to determine eligibility for perioperative chemotherapy, 28% (95% confidence interval, 24%–31%) of patients were ineligible. The exact proportion ineligible differed substantially with different formulas used to calculate creatinine clearance, but elderly patients were particularly likely to be ineligible.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field